Please assess the completion status of the following clinical trial:

Trial Title: A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Key Inclusion Criteria~* Diagnosis of advanced melanoma~* Prior treatment in a prespecified prior/parent ipilimumab study~* Men and women 18 years of age and older~First Reinduction:~* No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation~* Had experienced documented progressive disease after expanded clinical benefit~Extended Maintenance~* Received ipilimumab at any dose in a parent study~* Achieved expanded clinical benefit at the time of entry to current study~Follow-up:~* Received ipilimumab at any dose in a closing parent study~* Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up~Key Exclusion Criteria~* Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab~* Primary ocular or mucosal melanoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- First reinduction: Ipilimumab, 0.3 to 10 mg/kg (Type: EXPERIMENTAL): Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
- First reinduction: Ipilimumab, 3 to 10 mg/kg (Type: EXPERIMENTAL): Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
- First reinduction: Ipilimumab, 10 to 10 mg/kg (Type: EXPERIMENTAL): Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
- Extended maintenance: Ipilimumab, 0.3 mg/kg (Type: EXPERIMENTAL): Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
- Extended maintenance: Ipilimumab, 3 mg/kg (Type: EXPERIMENTAL): Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
- Extended maintenance: Ipilimumab, 10 mg (Type: EXPERIMENTAL): Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
- Follow-up (Type: NO_INTERVENTION): Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.

Based on this trial design, predict the completion outcome and termination type (if applicable).